Krystal Biotech, Inc. (KRYS) Stock: Price, Forecast & Analyst Target
Krystal Biotech, Inc. (KRYS) — MoonshotScore 97/100 (Exceptional band), calculated Oct 4, 2026. Price $322.28 (-0.93%), as of the Oct 2, 2026 trading session; market cap $9.54B. Expected results Nov 2, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Krystal Biotech, Inc. · KRYS · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Krystal Biotech develops redosable gene therapies for severe orphan diseases, with B-VEC at the front of a broader dermatology and rare-disease pipeline. Reported economics no longer resemble a pre-revenue biotechnology developer: sales, profit, and operating cash flow are established, while liquidity continues to build. The case now rests on whether that revenue base can keep expanding without the expense base outrunning demand.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Krystal Biotech (KRYS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $119M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of 8
- Altman Z 42.52 · Piotroski F 5
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional |
The score moved from 98 in the stored Oct 3, 2026 snapshot to 97 in the current publication computed Oct 4, 2026 (-1); the largest pillar moves were Momentum +1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $322.28 | |
| Change on the day | -0.93% | |
| 52-week range | $179.19–$382.54 | |
| Market capitalisation | $9.54B | |
| Price / earnings (trailing) | 38.97 | |
| Shares traded on the day | 426.1K | |
| Beta (volatility vs the S&P 500) | 0.54 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Krystal Biotech (KRYS): Strongly Bullish
82/100 · A+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the KRYS film — every key number, told as a short cinematic story
~2 min · open the film
What is Krystal Biotech (KRYS), and what does it report?
Short answer · as of
Krystal is a gene-therapy developer built around treatments that can be administered repeatedly rather than a diversified drug manufacturer.
Research dated 2026-09-13.
Krystal is a gene-therapy developer built around treatments that can be administered repeatedly rather than a diversified drug manufacturer. Its programs span severe inherited skin disorders, cystic fibrosis, and aesthetic dermatology, with B-VEC identified as the most advanced candidate. The economic task is to translate those programs into patient treatment; clinical progress by itself is not revenue.
What do the latest results show for Krystal Biotech (KRYS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $119M.
Research dated 2026-09-13.
Revenue advanced again in the latest reported period, while gross profit kept pace. Research spending and selling, general, and administrative expense each eased from the preceding period, allowing operating profit to rise even as net profit declined modestly. The immediate mechanism was operating leverage within the reported cost base, not a reduction in gross profitability.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $119.22M Aug 3, 2026
- Latest report · revenue estimate
- $120.93M Aug 3, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 3, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 3, 2026 | $119.22M | $120.93M | $1.7900 | $1.7000 |
| May 4, 2026 | $116.36M | $112.11M | $1.8300 | $1.4500 |
| Feb 17, 2026 | $107.11M | $105.35M | $1.7000 | $1.6200 |
| Nov 3, 2025 | $97.80M | $105.30M | $2.6600 | $1.1200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $119M | $55M | $1.79 (diluted) |
| Q1 FY2026 | $116M | $56M | $1.83 (diluted) |
| Q4 FY2025 | $107M | $51M | $1.72 (diluted) |
| Q3 FY2025 | $98M | $79M | $2.66 (diluted) |
What are the financial strengths and risks for Krystal Biotech (KRYS)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Krystal carries substantial cash and short-term investments, an additional pool of long-term investments, and little debt. Positive operating cash flow throughout the displayed run, paired with comparatively modest capital spending, has allowed liquid resources to rise while the company continues funding research and commercial overhead.
What should you watch next at Krystal Biotech (KRYS)?
Short answer · as of
The next earnings report is expected on Nov 2, 2026.
Research dated 2026-09-13.
Krystal’s scheduled earnings release puts revenue continuity, operating leverage, and cash conversion in focus. Useful confirmation would be another advance in revenue accompanied by resilient gross profit, controlled operating expenses, positive operating cash flow, and further preservation of liquidity.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Krystal Biotech compare with its peers?
Short answer
Krystal Biotech's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Development-stage rare-disease companies commonly depend on external capital while awaiting commercial validation; Krystal already reports recurring revenue, operating profit, net income, and positive operating cash flow. Yet its strategic identity remains that of a focused redosable gene-therapy platform rather than a diversified commercial biopharma business. That combination makes present earnings quality and candidate progression equally relevant comparisons.
| Company | Price | Market value | Score |
|---|---|---|---|
| $58.39 Oct 2, 2026 | $14.7B | 98 5-pillar Oct 4, 2026 | |
| Krystal Biotech (KRYS) — this page | $322.28 | $9.54B | 97 |
| $302.96 Oct 2, 2026 | $6.07B | 96 5-pillar Oct 4, 2026 | |
| $72.40 Oct 2, 2026 | $11.3B | 93 5-pillar Oct 4, 2026 | |
| $116.23 Oct 2, 2026 | $12.6B | 91 5-pillar Oct 4, 2026 | |
| $143.18 Oct 2, 2026 | $14.4B | 90 5-pillar Oct 4, 2026 | |
| $28.30 Oct 2, 2026 | $8.00B | 89 5-pillar Oct 4, 2026 | |
| $109.86 Oct 2, 2026 | $13.0B | 88 5-pillar Oct 4, 2026 | |
| $227.87 Oct 2, 2026 | $14.2B | 88 5-pillar Oct 4, 2026 | |
| $140.06 Oct 2, 2026 | $9.01B | 76 5-pillar Oct 4, 2026 | |
| $159.56 Oct 2, 2026 | $6.40B | 69 5-pillar Oct 4, 2026 | |
| $54.29 Oct 2, 2026 | $8.31B | 65 5-pillar Oct 4, 2026 | |
| $57.18 Oct 2, 2026 | $11.1B | 65 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $300.00 – $474.00
- Consensus target
- $395.20
- Median target
- $400.00
Consensus record · Captured .
Measured against a quoted price of $322.28 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 73
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 58
- Other transactions
- 15
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Krystal Biotech (KRYS)?
- Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target
- B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400
- BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating
- Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS
Krystal Biotech Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is B-VEC’s role in Krystal Biotech’s business?
B-VEC is Krystal’s most advanced therapeutic candidate and the clearest program-level test of its redosable gene-therapy approach. The remaining pipeline extends that platform across inherited skin disease, cystic fibrosis, and aesthetic dermatology.
Is Krystal Biotech still a clinical-stage biotechnology company?
Clinical development remains central to Krystal’s identity, but its financial profile is no longer pre-revenue. The company now reports substantial revenue, operating profit, net income, and positive operating cash flow alongside continued research spending.
Can Krystal fund its redosable gene-therapy pipeline internally?
Current operations are generating cash while liquid resources and investments comfortably exceed debt. That combination gives Krystal room to fund research without relying on balance-sheet depletion at the recent operating pace.
What do recent KRYS insider transactions show?
Recent recorded activity was dominated by sales and other transfers, with no purchases recorded. The pattern offers no affirmative buying signal, although the transactions alone do not establish why insiders sold.
What is the KRYS stock price today?
The last price recorded on this page for Krystal Biotech, Inc. (KRYS) is $322.28, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KRYS price target?
The analyst consensus price target for Krystal Biotech, Inc. (KRYS) is $395.20 (range $300.00 to $474.00, median $400.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (45 figures)
The 45 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 2100 Wharton Street, Suite 701, Pittsburgh, PA, 15203 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "2100 Wharton Street, Pittsburgh, PA, 15203, US". |
FMP — 38 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $322.28 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T10:44:33.061Z. | |
px.change | Change on the day | -0.93% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $9.54B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-04. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 2, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.change_abs | Change on the day, in dollars | −$3.03 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $119M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $179.19–$382.54 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 38.97 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 426.1K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.54 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Krish S. Krishnan | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 295 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result $0.00; FY2022 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 93.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.history.depth.2026-08-03.revenue_actual | Revenue · reported — report date 2026-08-03 | $119.22M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.revenue_estimated | Revenue · estimate — report date 2026-08-03 | $120.93M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_actual | EPS · reported — report date 2026-08-03 | $1.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_estimated | EPS · estimate — report date 2026-08-03 | $1.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_actual | Revenue · reported — report date 2026-05-04 | $116.36M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_estimated | Revenue · estimate — report date 2026-05-04 | $112.11M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_actual | EPS · reported — report date 2026-05-04 | $1.8300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_estimated | EPS · estimate — report date 2026-05-04 | $1.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_actual | Revenue · reported — report date 2026-02-17 | $107.11M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_estimated | Revenue · estimate — report date 2026-02-17 | $105.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_actual | EPS · reported — report date 2026-02-17 | $1.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_estimated | EPS · estimate — report date 2026-02-17 | $1.6200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_actual | Revenue · reported — report date 2025-11-03 | $97.80M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_estimated | Revenue · estimate — report date 2025-11-03 | $105.30M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | $2.6600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | $1.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 7.00× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt_range | Analyst price target, low to high | $300.00 – $474.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $395.20 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $400.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 73 transactions · 0 purchases, 58 sales, 15 other transactions · 9 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 42.52 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-03.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($119.22M) with the recorded estimate ($120.93M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-03.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.7900) with the recorded estimate ($1.7000) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 97 of 100 · Exceptional · pillars 96 / 97 / 39 / 98 / 80 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 98 (stored snapshot Oct 3, 2026) → 97 (current publication computed Oct 4, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-03. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-03.revenue_actual,earn.history.depth.2026-08-03.revenue_estimated,earn.history.depth.2026-08-03.revenue_actual.comparison,earn.history.depth.2026-08-03.eps_actual.comparison,earn.history.depth.2026-08-03.eps_actual,earn.history.depth.2026-08-03.eps_estimated,earn.history.depth.2026-05-04.revenue_actual,earn.history.depth.2026-05-04.revenue_estimated,earn.history.depth.2026-05-04.eps_actual,earn.history.depth.2026-05-04.eps_estimated,earn.history.depth.2026-02-17.revenue_actual,earn.history.depth.2026-02-17.revenue_estimated,earn.history.depth.2026-02-17.eps_actual,earn.history.depth.2026-02-17.eps_estimated,earn.history.depth.2025-11-03.revenue_actual,earn.history.depth.2025-11-03.revenue_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Krystal Biotech, Inc. | 2026-02-17 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-17 |
| Business description | Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash, investments and debt | Total debt: $8.85M; Liquidity basis: cash and short-term investments; Total liabilities: $141.52M; Cash and short-term investments: $845.63M; Cash and investments: $1.10B; Long-term investments: $257.29M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.10B; Cash and short-term investments: $845.60M; Long-term investments: $257.30M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Next earnings report | Date: 2026-11-02; EPS estimate: $1.91 per share; Revenue estimate: $129.65M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Insider transactions, last 180 days | Net shares: -129,691; Window days: 180; Price low: $179.25; Price high: $366.56; Buy transactions: 0; Distinct insiders: 4; Sell transactions: 57; Other transactions: 3; Total transactions: 60; Other transaction types: G-Gift: 1, M-Exempt: 2; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-04 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| What the sources do not tell us | Captured record · 3 entries
Each entry names a family of information the packet has no fact for.; The list is drawn from a fixed catalogue keyed to fact ids — it is not written per ticker and contains no generated text.; An absent family means our sources did not answer; it does not mean the company has nothing to report. | 2026-09-13 | COMPUTED | Derived from which sources answered this build |
Data provided for informational purposes only.
ETFs that hold KRYS
Funds in our ETF coverage that list KRYS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.30% |